April 25, Lyon, FRANCE

KUSTE BIOPHARMA, a clinical-stage biotechnology company founded in 2019 by seasoned life sciences entrepreneurs, focused on the development of compounds for inflammatory diseases, announced today that management will be participating in the following upcoming conferences:

• BioTrinity on 26-27 April 2022 in London
  Tuesday 26 april 15.25 pm : Mario Caria will present KUSTE BIOPHARMA
  in the session on Inflammatory diseases
  (for more info : Agenda ⇽ BioTrinity 2022 | OBN (UK) Ltd‌ on Glue Up)
• LSX World Congress 10-11 May 2022 in London
  Mario Caria, CEO, will be available for one-on-one meetings
• Bio€quity Europe 16-18 may 2022 in Milan
  Presentation by Mario Caria, CEO

KUSTE Biopharma is a clinical-stage biotechnology company founded by seasoned life sciences entrepreneurs. KUSTE develops molecules for severe chronic inflammatory diseases.

The company’s lead indication is Interstitial Cystitis also called Bladder Pain Syndrome (IC/BPS). Brimapitide, a small penetrating peptide, JNK inhibitor, demonstrated to be safe and effective in large patient pool, has been developed for IC/BPS in a Phase 2a. KUSTE is now launching Phase 2b. Among other indications we are developing Ulcerative Colitis now in Pre-clinical, preparing for Phase 1/2a.

For more information : www.kustebiopharma.com

PRESS CONTACT
Bénédicte Freyler
benedicte.freyler@kustebiopharma.com